| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.5 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |